Good Sport
2 weeks ago
https://www.sec.gov/ix?doc=/Archives/edgar/data/1141788/000168316824006475/health_8k.htm
8K is just out. Pretty straight forward on dismissal...
"Item 8.01 Other Events
On September 13, 2024, the United States District Court for the Northern District of Georgia granted Health Discovery Corporationβs (βHDCβ or the βCompanyβ) motion for summary judgment in full and entered judgment in favor of all defendants on all counts in the shareholder derivative lawsuit brought by Vennwest Global Technologies, Inc. (βVennwestβ). The Vennwest lawsuit, which was initially filed in September 2020, alleged misconduct by the Company and its board of directors (βBoardβ) in connection with approving a series of loans to HDC by certain directors and shareholders of HDC. The Vennwest lawsuit contains virtually identical claims against HDC that shareholders William Quirk and Cindy Bear had alleged, which lawsuit was also dismissed. The loans at issue were sought by the Company to allow it to meet its financial obligations in connection with litigation that was ongoing at the time. The District Court found that the loans were presented to and approved by the Board, in all respects, in compliance with Georgiaβs conflicting interest transaction statutes, requiring the dismissal of all claims asserted by the plaintiff. The judgment affords HDC the recovery of its costs associated with the lawsuit (which does not include the recovery of its legal fees).
The Courtβs order and judgment represent a complete refutation of these baseless claims and a total vindication of the Companyβs longstanding position that these claims were entirely without merit and served only to distract the Company and deplete its resources to the detriment of its shareholders.
Board member Colleen Hutchinson stated: βWe are gratified by the decision of the Court in this matter. Now that this matter has been resolved, the Board looks forward to focusing on the development of the Companyβs technology without the unnecessary distraction and cost that this lawsuit has caused over the previous four years.β
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HEALTH DISCOVERY CORPORATION
Registrant
Dated: September 18, 2024 By: /s/ Colleen Hutchinson
Colleen Hutchinson
Board Member
chazzy1
3 weeks ago
Yes, that is a very good point, Alan. It was obviously listed as open source in error, however, it is the responsibility of HDC to force them to remove the listing. I am 99.999% sure that the Board of HDC is not aware of this. Thank you for calling it to everyone's attention!
BTW, could you provide the link which shows SVM-RFE to be open source? This would be most helpful in bringing this oversight/error to the Board's attention. Thanks!
alan81
3 weeks ago
I just asked copilot about open source versus royalty payment machine learning algorithms:
copilot claims scikit-learn, tensorflow, pytorch, xgboost, lightgbm, and Keras are all open source (free to use) while SAS, Matlab, and IBM Watson require a royalty payment. I then specifically asked it about SVM-RFE and it said it is available as open source :-/
chazzy1
3 weeks ago
Buylow2, if it's any consolation to you, I don't like how long this is taking either. However, it is what it is. Do you think that Dr. Hauser is intentionally slow walking the super K submission to the SEC, and the monetization process? No, I think that his incentive is to get this done as soon as possible. To those of us who are unfamiliar with the process, this may seem to be proceeding at a snail's pace when, in actuality, it may be proceeding as fast as possible. Being on the outside looking in, we just don't know what all may be involved in this process.
chazzy1
3 weeks ago
Good Sport, I agree that $180K is a good incentive to just kill time, however, the stock option is a bigger piece of Dr. Hauser's compensation package, and represents a much greater incentive to monetize HDC's SVM-RFE technology. Although he is not an MD, his expertise is in the biosciences as well as in business development.
chazzy1
3 weeks ago
LocWolf, you present some interesting thoughts, theories and speculations. However, even if Coleen's motives were as you suggest, I doubt that Dr. Hauser would have accepted the CEO position in the absence of a strong belief that he could monetize HDC's patented SVM-RFE technology, specifically in the field of medical diagnostics. JMHO.